Brain Malignancies Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Brain Malignancies Steering Committee (BMSC) was established in November of 2010.

Mission Statement

The BMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in brain cancer clinical research by addressing the design, prioritization and evaluation of phase 2, and phase 3 clinical trials in both adult and pediatric brain cancers.

Roster of Brain Malignancies Steering Committee (BMSC) members

BMSC Activities

Clinical Trials Planning Meetings (CTPMs)


Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee.

Trial ID NCT ID Trial Title
PBTC-039 NCT01964300 Phase II study of Peginterferon α-2b for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma
COG-ACNS1221 NCT02017964 A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age
COG-ACNS1123 NCT01602666 A Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
Alliance-A071101 NCT01814813 A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Trial Comparing Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine or Placebo in Combination with Bevacizumab (Avastin®) in the Therapy of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
PBTC-036 NCT01836549 A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor (PNET) and Diffuse Intrinsic Pontine Glioma (GBM)
RTOG-1205 NCT01730950 A Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
COG-ACNS1022 NCT01553149 A Phase II Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Low-Grade CNS Gliomas
PBTC-033 NCT01514201 A Feasibility and Phase II Study of ABT888, an oral poly( ADP-ribose) polymerase inhibitor, and concurrent radiation therapy, followed by ABT888 and temozolomide, in children with newly diagnosed high-grade or diffuse pontine gliomas (DIPG)

Find all NCI-sponsored clinical trials.

CCCT Contact: Abdul Tawab Amiri, Ph.D